Holen Sie sich die Stockscreener-App
76.77
4.89%
3.623
Schlusskurs vom Vortag:
$73.15
Offen:
$73.15
24-Stunden-Volumen:
1.01M
Relative Volume:
0.91
Marktkapitalisierung:
$2.59B
Einnahmen:
$55.63M
Nettoeinkommen (Verlust:
$-158.10M
KGV:
-9.1177
EPS:
-8.4202
Netto-Cashflow:
$-203.94M
1W Leistung:
+9.91%
1M Leistung:
+33.85%
6M Leistung:
+76.34%
1J Leistung:
+226.91%
1-Tages-Spanne:
$73.15
$77.00
1-Wochen-Bereich:
$63.89
$77.00
52-Wochen-Spanne:
$21.02
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
76.80 | 2.40B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | Wedbush | Neutral |
| 2026-03-17 | Eingeleitet | TD Cowen | Buy |
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics R&D chief sells $397,670 of common stock - Investing.com
Form 4 Nektar Therapeutics For: 2 July By Investing.com - Investing.com Nigeria
Nektar Therapeutics R&D chief sells $397,670 of common stock By Investing.com - Investing.com UK
Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves - timothysykes.com
How Nektar Therapeutics’ Broad FTSE Russell Index Inclusion Will Impact Nektar Therapeutics (NKTR) Investors - simplywall.st
Jonathan Zalevsky (NKTR) sells 5,737 shares via 10b5-1 plan - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Investors to Reach Out - ACCESS Newswire
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Index - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2500 Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Value Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Index - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Growth Benchmark - marketscreener.com
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000 Value Benchmark - marketscreener.com
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics Actuals & Estimates (NASDAQ:NKTR) - TradingView
Nektar Therapeutics(NasdaqCM: NKTR) added to Russell Small Cap Completeness Index - marketscreener.com
Price to sales forward of Nektar Therapeutics – SWB:ITH0 - TradingView
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Price to earnings forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Enterprise value to EBITDA forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Price to book forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Enterprise value to EBIT forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Enterprise value to revenue forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Price to sales forward of Nektar Therapeutics – DUS:ITH0 - TradingView
Nektar Therapeutics Company Profile & Introduction - Moomoo
NKTR Forecast — Price Target — Prediction for 2027 - TradingView
A419UB Forecast — Price Target — Prediction for 2027 - TradingView
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year - AOL.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - Stockhouse
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - Yahoo Finance
Nektar Therapeutics (NKTR) Institutional Confidence - TradingKey
Nektar Therapeutics chief R&D officer sells $336,211 in stock - Investing.com UK
Nektar Therapeutics chief R&D officer sells $336,211 in stock By Investing.com - Investing.com Nigeria
Form 4 Nektar Therapeutics For: 22 June By Investing.com - Investing.com South Africa
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-21 | Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Certain Performance Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
NKTR Technical Analysis & Stock Price Forecast - Intellectia AI
NKTR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):